To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL

Inclusion Criteria:

• Stage III or IV, histologically confirmed relapsed or refractory MCL as reviewed by the SI
• Is CD20 positive (by immunohistochemistry or FACS)
• Is Cyclin D positive (by immunohistochemistry or FACS)
• Has received prior chemotherapy (required minimum of 1 prior therapies)
• Has received prior treatment with Rituxan
• Has an ECOG Performance Status (PS) 0-2
• Is greater than or equal to 18 years of age
• Has appropriate laboratory values (please refer to protocol for specific laboratory values)
• If a history of cardiac disease is indicated, patient has an LVEF greater than or equal to 50% (MUGA)
• Has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential)
• If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a period of 2 months thereafter
• Has signed a Patient Informed Consent Form
• Has signed a Patient Authorization Form

Exclusion Criteria:

• Has other lymphomas not classified as MCL
• Has had prior treatment with Gemzar and/or Novantrone
• A history of known hypersensitivity to Gemzar, Novantrone, Rituxan, or any component of these drugs
• Has a history of hypersensitivity to murine-cell derived therapeutics
• Has a LVEF indicative of a cardiac condition (LVEF < 50%)
• Is receiving concurrent immunotherapy
• Has evidence of CNS involvement
• Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
• Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs
• Is a pregnant or nursing woman
• Is unable to comply with requirements of study

ITT population

During the whole treatment period, up to 30 days following last dose.

For treated patients only, assessed at each treatment visit.